Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Naru Kondo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9873-4787; OpenAlex author ID A5091178168. Sources: OpenAlex.

Their work

Papers
25 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 4 papers · 2021: 6 papers · 2022: 7 papers · 2023: none · 2024: 1 paper

Papers 25

  1. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a ph… First author DOI 10.1002/jhbp.1412↗
  2. Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using invers… Co-author DOI 10.1002/jhbp.1151↗
  3. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. Co-author DOI 10.1007/s00423-021-02339-x↗
  4. Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pan… Co-author DOI 10.1007/s12328-022-01621-9↗
  5. Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.12.009↗
  6. Impact of disintegrin and metalloproteinase domain-containing protein 12 on pancreatic ductal adenocarcinoma treated with surgical resection and perioperative … Co-author DOI 10.1016/j.pan.2022.03.018↗
  7. Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2022.04.004↗
  8. Reply to Letter to the Editor "Re: Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upf… Co-author DOI 10.1159/000527660↗
  9. Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer. Co-author DOI 10.1007/s00423-020-02025-4↗
  10. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. Co-author DOI 10.1007/s11605-021-04978-3↗
  11. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial… Co-author DOI 10.1016/j.ejca.2021.10.012↗
  12. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.01.022↗
  13. Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery. Co-author DOI 10.1159/000520064↗
  14. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09278-9↗
  15. Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status. Co-author DOI 10.1002/jhbp.687↗
  16. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection. Co-author DOI 10.1002/jhbp.737↗
  17. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis. Co-author DOI 10.1007/s00423-020-01914-y↗
  18. Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.08.019↗
  19. Prognostic impact of postoperative complication after pancreatoduodenectomy for pancreatic adenocarcinoma stratified by the resectability status. Co-author DOI 10.1002/jso.25066↗
  20. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuva… First author DOI 10.1016/j.pan.2017.12.014↗
  21. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-017-3274-0↗
  22. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Co-author DOI 10.1038/bjc.2016.175↗
  23. Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-016-5120-8↗
  24. An Increased Number of Perineural Invasions Is Independently Associated With Poor Survival of Patients With Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000413↗
  25. Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgic… Co-author DOI 10.1002/jso.21955↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Uemura · 24 shared papers, 2011–2024 · strength 2.84
  2. Shin’ya Takahashi · 21 shared papers, 2016–2024 · strength 2.69
  3. Yoshiaki Murakami · 23 shared papers, 2011–2024 · strength 2.69
  4. Kenjiro Okada · 18 shared papers, 2018–2024 · strength 2.48
  5. Hiroyuki Otsuka · 14 shared papers, 2020–2022 · strength 1.93
  6. Tatsuaki Sumiyoshi · 13 shared papers, 2020–2024 · strength 1.90
  7. Taijiro Sueda · 8 shared papers, 2011–2021 · strength 0.58
  8. Takeshi Sudo · 4 shared papers, 2011–2024 · strength 0.43
  9. Ryuta Shintakuya · 2 shared papers, 2018–2024 · strength 0.29
  10. Takuya Sakoda · 2 shared papers, 2021–2022 · strength 0.29
  11. Yasutaka Ishii · 2 shared papers, 2021–2022 · strength 0.27
  12. Tomofumi Tsuboi · 2 shared papers, 2021–2022 · strength 0.27
  13. Takumi Harada · 1 shared paper, 2024 · strength 0.21
  14. Kenta Baba · 1 shared paper, 2024 · strength 0.21
  15. Eiso Hiyama · 2 shared papers, 2016–2021 · strength 0.19
  16. Yoshiyuki Shibata · 1 shared paper, 2022 · strength 0.15
  17. Takuro Yamaguchi · 1 shared paper, 2021 · strength 0.13
  18. Naoto Hadano · 1 shared paper, 2016 · strength 0.06
  19. Toshiaki Komo · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.